This current price of .37c is extremely undervalued. 1. Total...

This current price of .37c is extremely undervalued.

1. Total remaining holders 35,985,053 shares after top 20.
Company has stated that there is enough cash to complete tt-034 without further CR

2. Hepatitis C market is forecast to grow by 230 per cent, peaking at $15.5bn in 2022.

3. TT-034 will report efficacy data June est. July next year.

4. Gilead gained rights to Sofosbuvir (GS-7977) through the $11 billion Pharmasset acquisition deal at phase 1/11. Barclays values it at $3.8 billion.

4. Any good releases regarding safety will increase sp.

The successful outcome of the TT-034 trial will drive SP growth. This time next year will be very interesting.